BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V}

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BRAVEHEART who wrote (14)	1/25/1999 6:30:00 PM
From: BRAVEHEART	Read Replies (1) of 423

LXR UPDATE: Hi Gang, Since my post on the 12th a few key developments have occurred with LXR. 1. The company has just about resolved a legal issue which was a small thorny issue with investors. The outcome appears to be quiet satisfactory with little damages to the company of any lasting consequence. "The settlement relates to three class action lawsuits: Katz v. Blech, Degulis v. LXR Biotechnology, and In re D. Blech & Co. Securities Litigation. The agreement in principle achieved with plaintiffs' class action counsel provides for dismissal of all claims against LXR and the five former LXR directors named as defendants in those cases. The settlement amount is $500,000, of which approximately $155,000 will be paid by LXR and approximately $345,000 will be paid by the Company's insurer." biz.yahoo.com 2. The company will hold a Conference call on Friday. It is a limited conference call. I intend on participating. I will post my understanding soon thereafter. I hope they layout what one can expect over the ensuing months. I personally believe there will be several important developments over the next few months. Given the Stokes ( TA ) I would hope that there is nothing of importance announced until say mid next week or the following week. The conference should reach existing shareholders and interested potential shareholders as well as lay out certain expectations for the remainder of the year to Brokerages etc. I think we all expect certain key developments with respect to Elerix and Cardisol. In particular the completion of animal studies and filing with the FDA for Human clinicals. As significant will be the potential for collaborations with Big pharma. Hopefully the conference call will give us some clues as to a timeline of expectations. I certainly believe this company is poised to make major strides this year. In fact I would guess there will be a few surprises along the way. PS: Stokes suggest a bottom. I would expect buying momentum to take us back to say $1.75. If the conference call is really encouraging coupled with an expectation of a key collaboration in the near term we should be able to break that $2 threshold. Once such a collaboration does occur It will certainly be good news from a valuation perspective. clearstation.com BEST WISHES LONE WOLF

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next